|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 10.30 USD | -1.67% |
|
-0.47% | -28.95% |
| 07-30 | Daxor Launches Blood Testing Lab in Eastern Kansis | MT |
| 07-30 | Daxor Corporation Initiates Outpatient Blood Volume Analysis Program in Kansas | CI |
| Market Cap | 61.07M 52.89M 49.3M 45.35M 85.61M 5.81B 86.57M 579M 227M 2.91B 229M 224M 9.62B | P/E 2026 * |
-49.9x | P/E 2027 * | -349x |
|---|---|---|---|---|---|
| Enterprise Value | 61.07M 52.89M 49.3M 45.35M 85.61M 5.81B 86.57M 579M 227M 2.91B 229M 224M 9.62B | EV / Sales 2026 * |
5.13x | EV / Sales 2027 * | 2.94x |
| Free-Float |
46.74% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Daxor Corporation
| 1 week | -0.47% | ||
| Current month | -0.19% | ||
| 1 month | +0.96% | ||
| 3 months | -3.44% | ||
| 6 months | -14.52% | ||
| Current year | -28.95% |
| 1 week | 10.11 | 11 | |
| 1 month | 10.05 | 11.97 | |
| 3 years | 6.55 | 14.76 | |
| 5 years | 6.55 | 14.76 | |
| 10 years | 3.4 | 24.08 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 56 | 31/12/2012 | |
Robert Michel
DFI | Director of Finance/CFO | 69 | 27/09/2018 |
John Jefferies
CTO | Chief Tech/Sci/R&D Officer | - | 04/06/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
James Lombard
BRD | Director/Board Member | 91 | 31/12/1988 |
| Chairman | 56 | 13/02/2017 | |
Edward Feuer
BRD | Director/Board Member | 70 | 21/06/2016 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -1.67% | -0.47% | +5.12% | +9.36% | 61.07M | ||
| +0.48% | +3.96% | +24.98% | +114.47% | 15.24B | ||
| -0.91% | +4.59% | +56.35% | +153.60% | 12.78B | ||
| -0.66% | +5.59% | -3.01% | +32.34% | 9.36B | ||
| -0.21% | +3.84% | +36.46% | +133.96% | 7.86B | ||
| +0.47% | -0.19% | -16.81% | -17.62% | 7.39B | ||
| +3.44% | +3.78% | +14.69% | +48.27% | 6.38B | ||
| +0.72% | -0.13% | +9.69% | +24.39% | 4.76B | ||
| +0.42% | -2.06% | +9.90% | +6.83% | 4.03B | ||
| -0.03% | +3.76% | - | - | 3.81B | ||
| Average | +0.43% | +3.34% | +15.26% | +56.18% | 7.96B | |
| Weighted average by Cap. | +0.26% | +4.38% | +20.85% | +79.34% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 11.9M 10.31M 9.61M 8.84M 16.68M 1.13B 16.87M 113M 44.31M 566M 44.69M 43.71M 1.88B | 20.8M 18.01M 16.79M 15.45M 29.16M 1.98B 29.48M 197M 77.45M 990M 78.12M 76.4M 3.28B |
| Net income | -1.2M -1.04M -969K -891K -1.68M -114M -1.7M -11.38M -4.47M -57.09M -4.51M -4.41M -189M | -200K -173K -161K -149K -280K -19.02M -284K -1.9M -745K -9.52M -751K -735K -31.51M |
| Net Debt | - | - |
Employees
-
Sector
Closed End Funds
| Date | Price | Change | Volume |
|---|---|---|---|
| 05/08/26 | US$10.48 | -0.38% | 315 |
| 04/08/26 | US$10.52 | -3.04% | 3,119 |
| 03/08/26 | US$10.85 | +3.33% | 689 |
| 31/07/26 | US$10.50 | - | 870 |
| 30/07/26 | US$0.000000 | -100.00% | 115 |
Sell
Buy

Mean consensus
BUY
Number of Analysts
2
Last Close Price
10.48USD
Average target price
22.50USD
Spread / Average Target
+114.69%
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- DXR Stock
- DXR Stock
Select your edition
All financial news and data tailored to specific country editions

















